Prognostic significance of hormone receptors in endometrial cancer.
BACKGROUND
Endometrial carcinoma is the most common female pelvic genital malignancy. Many studies suggest that approximately 75% of all endometrial cancers are clinical Stage I. More than 50% of cancer deaths are in patients with clinical Stage I disease. As a result, prognostic factors have been evaluated in an attempt to identify those patients with presumed early stage disease who will be at high risk for recurrence. Recently, hormone receptor status (estrogen [ER], progesterone [PR]) in endometrial cancer has been suggested to be a prognostic factor.


METHODS
Two hundred seventeen patients with Stage I and II endometrial cancers were evaluated for cytoplasmic steroid-receptor status. These results were compared with other prognostic factors in both univariant and multivariant analysis.


RESULTS
When ER and PR and combined ER/PR status were analyzed separately, patients with receptor-positive lesions had significantly better disease-free survival than those with receptor-negative lesions. The receptor status was also a significant independent prognostic factor when evaluated by stepwise proportional hazards regression analysis.


CONCLUSIONS
Hormone receptor status in endometrial cancer appears to be an important prognostic factor.
Creasman
W T
WT
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425.
D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012044:Regression Analysis; D016019:Survival Analysis
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone